WithdrawnPHASE1, PHASE2NCT01419704
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
Studying Alpha-thalassemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Talaris Therapeutics Inc.
- Principal Investigator
- Suzanne T Ildstad, MDTalaris Therapeutics Inc.
- Intervention
- Enriched Hematopoetic Stem Cell Infusion(biological)
- Eligibility
- 45 years · All sexes
- Timeline
- 2011 – 2016
Study locations (3)
- Northwestern Memorial Hospital, Chicago, Illinois, United States
- University of Louisville, Louisville, Kentucky, United States
- Duke University Medical Center, Durham, North Carolina, United States
Collaborators
Duke University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01419704 on ClinicalTrials.govOther trials for Alpha-thalassemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06591936Genetic Profile of Alpha Thalassemia Children at Sohag University Hospital .Sohag University
- RECRUITINGNANCT06539169FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare DiseasesxCures
- RECRUITINGEARLY PHASE1NCT06107400Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring DiseaseThe 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
- RECRUITINGPHASE2NCT05664737A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-ThalassemiaBristol-Myers Squibb
- ACTIVE NOT RECRUITINGPHASE3NCT04770753A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)Agios Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE3NCT04770779A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Agios Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGNANCT02692872Screening for Alpha Thalassemia in Healthy VolunteersNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT04872179International Registry of Patients With Alpha ThalassemiaUniversity of California, San Francisco